



January 20, 2026

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

Trading Symbol: ZOTA

Sub: Press Release on Davaindia Reinforces Confidence in Quality-Assured Generic Medicines, Backed by Independent Drug Quality Assessment

With reference to the captioned subject; we, Zota Health Care Limited are forwarding herewith enclosed a copy of press release on Davaindia Reinforces Confidence in Quality-Assured Generic Medicines, Backed by Independent Drug Quality Assessment.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

Ashvin Variya
(Company Secretary & Compliance Officer)
Place: Surat

Encl: Press Release

Registered Office:

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat-395002 Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web: www.zotahealthcare.com

CIN: L24231GJ2000PLC038352

Davaindia Reinforces Confidence in Quality-Assured Generic Medicines, Backed by Independent Drug Quality Assessment

Study by MESH Across 131 medicines spanning 22 therapeutic categories validates 100% quality compliance of Generic Medicines including Davaindia, matching branded drugs while offering significant cost advantages

Surat, January 20, 2026: Zota Health Care Limited ("the Company"), through its retail generic pharmacy chain **Davaindia**, is reaffirming **the role of quality-assured generic medicines in improving treatment continuity and healthcare affordability in India**. With out-of-pocket expenditure continuing to influence whether patients can sustain prescribed therapies, the Company believes that wider adoption of regulated, evidence-backed generics is critical to bridging the gap between prescription intent and long-term adherence.

This perspective, central to Davaindia's operating philosophy, is supported by recent findings from one of the largest private-led quality assessments of generic medicines conducted in India. The assessment, **led by hepatologist and clinical researcher Dr Cyriac Abby Philips under the Mission for Ethics and Science in Healthcare (MESH)**, evaluated whether the quality of commonly used generic medicines meet established pharmacopoeial standards across a broad range of therapies.


The assessment tested 131 medicines spanning 22 therapeutic categories, including widely prescribed treatments for cardiovascular diseases, diabetes, liver disorders, pain management, and infections. Samples were sourced from seven distribution channels, encompassing leading branded medicines, branded generics (generics manufactured or marketed by big brands), local trade generics, **Davaindia Generics**, and government supply schemes such as **Jan Aushadhi and the Kerala Medical Services Corporation**. Each medicine was tested against Indian Pharmacopoeia benchmarks, including drug content, dissolution, uniformity, impurities, and physical characteristics.

The findings highlighted that all generic medicines tested met Indian quality standards. At the same time, the assessment highlighted significant price differentials, with generics available at substantially lower prices than leading branded medicines. The results reinforce that concerns around the quality of generics are not supported by evidence, while the affordability advantage remains meaningful, particularly for patients requiring long-term chronic therapy.



Commenting on the relevance of these findings for India's healthcare ecosystem, Ketan Kumar Zota, Chairman, Zota Health Care Limited said, *"Independent quality assessments by MESH help bring clarity to a conversation that has historically been shaped more by perception than data. For platforms like Davaindia, this validation reinforces the importance of building a tightly controlled, quality-assured generic ecosystem at scale. Our approach has been to design the business around disciplined sourcing, regulatory compliance, and reliable availability, so that affordability is delivered alongside consistency and confidence, and evidence-backed generics translate into real-world treatment continuity for patients"*

For the healthcare system at large, such validation carries important implications. Historical apprehensions around generic medicines have influenced prescribing behaviour and patient confidence, often resulting in higher treatment costs or interruptions in therapy. Independent quality assessments support a more data-led approach to medicine selection, especially in chronic conditions where sustained adherence is critical to outcomes.

Against this backdrop, **Davaindia - the retail generic pharmacy chain**, represents an organised execution model focused on quality assurance, scale, and affordability. Davaindia follows a 100% private-label approach, with medicines sourced exclusively from WHO-GMP-certified manufacturing facilities and supported by structured quality control and compliance processes. The Davaindia portfolio comprises over 2,000 SKUs across chronic and acute therapy areas, with a strong emphasis on medicines that typically form a recurring component of household healthcare expenditure.



By streamlining procurement and reducing intermediary-heavy supply chains, the platform enables price savings of approximately 30% to 90% compared to branded alternatives, while adhering to applicable regulatory and quality standards. Over 16 lakh customers are served every month by Davaindia, with approximately 80% being repeat customers a strong testament to the confidence and trust placed in the brand.

Tablet	Telmisartan 40 mg & Hydrochlorothiazide 12.5 mg	Levocarnitine 500 mg	Rabeprazole 40 mg	Aceclofenac 100 mg, Paracetamol 325 mg & Serratiopeptidase 15 mg
Manufacturer	Same Manufacturer			
Marketed By	Foreign Pharma MNC 	Foreign Pharma MNC 	Foreign Pharma MNC 	Foreign Pharma MNC 
MRP	₹ 187.9 ₹ 25.0	₹ 404.95 ₹ 82.0	₹ 202.5 ₹ 35.0	₹ 147.48 ₹ 35.0

As of **31 December 2025**, Davaindia operated **2,331 active stores across India**, including

- 1,438 company-owned company-operated (COCO) stores and
- 893 franchisee-owned franchisee-operated (FOFO) stores.
- During Q3 FY26, the network expanded by 276 stores, including 231 COCO and 45 FOFO outlets
(COCO stores are operated by Davaindia Health Mart limited, the wholly owned subsidiary of the Company)

reflecting increasing consumer acceptance of organised generic retail. The Company has also adopted a hyperlocal fulfilment model, leveraging its physical store network to support timely doorstep delivery of medicines.

Further strengthening its brand connect and national presence, **cricket icon Mahendra Singh Dhoni and renowned actor Suniel Shetty** serve as **brand ambassadors for Davaindia**, reinforcing the company's commitment to trust, reliability, and nationwide impact.

As India continues to balance affordability, access, and quality in healthcare delivery, the convergence of independent evidence, regulatory oversight, and disciplined execution is expected to shape the next phase of generic medicine adoption. **Davaindia remains focused on strengthening its national footprint while supporting broader confidence in quality-assured generics across the healthcare ecosystem.**

Annexure

Illustrative Pricing of Selected Davaindia Generic Medicines and Branded Equivalents

Product	Packing	Davaindia MRP	Branded MRP (Approx.)
Rosuvastatin 10mg	10 Tablets	₹23	₹233
Calcium & Vitamin D3	15 Tablets	₹15.50	₹89
Telmisartan 40mg	10 Tablets	₹20.50	₹85
Pantoprazole + Domperidone	10 Capsules	₹23	₹150
Levocetirizine + Montelukast	10 Tablets	₹25	₹175
Vitamin D3 60,000 IU	4 Capsules	₹28	₹132

Key Highlights and Recent Developments

- Generic medicines offering the same quality as branded medicines at up to 30-90% lower prices
- Nationwide campaign to make life-saving medicines affordable and accessible to every citizen.
- One new Dava India store launched every 12 hours.
- Strong and growing trust among patients, customers, and investors.
- Davaindia has 2000+ SKUs in its portfolio.
- 2,331 Dava India stores operating across India.
- ₹350 crore raised through QIP from domestic and international investors.

About Zota Health Care Limited:

Zota Health Care Ltd. (Zota), listed on the NSE, has been a key player in the Indian healthcare industry since 2000. Headquarters in Surat, Zota's team of over 520 professionals drives its growth and strong market presence. The company specializes in the development, manufacturing, and marketing of high-quality pharmaceutical, ayurvedic, nutraceutical, and over-the-counter products.

Zota operates through three main divisions: marketing, export, and the retail pharmacy chain. In 2017, Zota launched Davaindia, a generic pharmacy chain offering over 2,000 SKUs of quality medicines. Davaindia's strategic business model ensures efficient management of the entire product life cycle through backward and forward integration.

Zota is renowned for its innovative Research and Development team, consistently investing in pioneering healthcare solutions, reinforcing its reputation in the industry. For more information, visit: www.zotahealthcare.com

For details please contact:

Ashvin Variya	Siddesh Chawan	Ajit Mishra
CS, Zota Health Care Ltd	Ernst & Young LLP, Investor Relations	Ernst & Young LLP, Investor Relations
E: cszota@zotahealthcare.com	E: Siddesh.Chawan@in.ey.com	E: Ajit.J.Mishra@in.ey.com

***Disclaimer:** Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political, or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Zota Health Care Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*